Make sure you stop by Booth #2109 or register for the workshop we are running in collaboration with Alpha MED Scienctific, a manufacturer of the MED64.
Private equity firm Calculus Capital, a leading EIS and VCT investor, has further expanded its life science portfolio, by investing £2.5m in Cambridge-based Axol Bioscience (Axol), a provider of stem cells produced from reprogrammed human blood and tissue cells.
Cambridge, UK, 26 July 2016: Axol Bioscience, a biotechnology company specialising in the supply of human induced pluripotent stem cell (iPSC)-derived cells, and Metrion Biosciences, a specialist ion channel drug discovery business, have signed a collaboration agreement to improve, standardise and more accurately predict the risk of human clinical pro-arrhythmias. This is in accordance with the FDA’s Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative, which aims to revise cardiac safety testing regulations.
Under the terms of the agreement, Metrion will use Axol’s human iPSC-derived cardiomyocytes to carry out ion channel screening, cardiac safety testing and translational phenotypic assays. Combining Metrion's contract research services and assay development capabilities with Axol’s human iPSC-derived cells and culture reagents will provide a source of well-validated, CiPA-compliant stem cell-derived assays and services for use in predictive toxicology as well as drug discovery screening.
BIRMINGHAM, CAMBRIDGE, HUDDERSFIELD (UK), HANNOVER (Germany), BARCELONA (Spain), 9 June 2016: The MESO-BRAIN consortium has received a prestigious award of €3.3 million in funding from the European Commission as part of its Future and Emerging Technology (FET) scheme. The project aims to develop three-dimensional (3D) human neural networks with specific biological architecture, and the inherent ability to interrogate the network’s brain-like activity both electrophysiologically and optically. It is expected that the MESO-BRAIN will facilitate a better understanding of human disease progression, neuronal growth and enable the development of large-scale human cell-based assays to test the modulatory effects of pharmacological and toxicological compounds on neural network activity. The use of more physiologically relevant human models will increase drug screening efficiency and reduce the need for animal testing.
Cambridge, UK, 1 June 2016: Axol Bioscience, a biotechnology company specialising in the supply of human induced pluripotent stem cell (iPSC)-derived cells has expanded its range of drug discovery and disease modelling tools. Axol will launch three exciting products at International Society for Stem Cell Research (ISSCR) 2016 taking place in San Francisco, CA from 22 - 25 June. This includes: Human iPSC-Derived Atrial Cardiomyocytes, Human iPSC-Derived Endothelial Colony Forming Cells (ECFCs) and axolGEMs (Genetically Edited Models), Axol’s new range of isogenic human iPSC-derived cells carrying disease-relevant mutations developed in partnership with Horizon Discovery plc. Axol and its collaborators will also be presenting an Innovation Showcase and posters highlighting the characteristics and functional applications of its human iPSC-derived neural cells and cardiomyocytes.
Cambridge, UK, 12 May 2016: Axol Bioscience, a biotechnology company specialising in the supply of human iPSC-derived cells has expanded its range of neuroscience research tools to include an iPSC-Derived Astrocyte Progenitor Kit and iPSC-Derived Mature Astrocyte Kit. Axol iPSC-Derived Astrocyte Kits include cryopreserved cells, optimised media and supplements. The new kits offer researchers a complete culture system that is easy to use and promotes long-term cell viability for use in disease modelling and drug discovery applications.
Cambridge, UK, 28 April 2016: Axol Bioscience, a biotechnology company specialising in the supply of primary and stem cell-derived human cells for use in disease modelling and drug discovery, announces the launch of its Custom Cell and Tissue Sourcing service. The new service will be of use to all researchers working in these areas who require access to primary human cells and tissues. These can be difficult to obtain, especially when studying rare diseases or specific donor criteria are required. Axol aims to provide cells and tissues that meet specific research requirements to enable the development of highly relevant cellular models that better reflect the biology of the tissue or disease.
Cambridge, UK, 19 April 2016: Axol Bioscience, a biotechnology company, specialising in the use of stem cell technology to manufacture disease-relevant cell based assay systems for drug discovery and disease modelling, today announced that Steve Finkbeiner, MD, PhD has joined its Scientific Advisory Board. Dr Finkbeiner is a leading neuroscientist who will guide Axol in expanding its range of induced pluripotent stem cell (iPSC)-derived neural cells and culture systems to ensure that the company continues to bring innovative products to market. Dr Finkbeiner is renowned for his research in neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), and Huntington’s, Parkinson’s and Alzheimer’s diseases. He is perhaps best known for his invention of a robotic imaging device that has helped to elucidate the mechanisms behind learning, memory formation and neurodegeneration.
Cambridge, UK, 12 January 2016: Axol Bioscience, a biotechnology company, specialising in the use of stem cell technology to manufacture disease relevant cell based assay systems to the drug discovery industry, today announced Prof Xianmin Zeng, PhD as Chief Scientific Officer (CSO). Prof Zeng is an accomplished biologist with over 15 years of academic expertise in the development of stem cell technologies and its applications. A biotech entrepreneur with an extensive list of peer-reviewed publications, she is a well-established and internationally-recognised leader in the creation of disease models for drug discovery.
Cambridge, UK, 24 November 2015: Horizon Discovery Group plc (LSE:HZD) (Horizon), the international life science company supplying research tools and services to organizations engaged in genomics research and the development of personalized medicines, and Axol Bioscience Ltd (Axol), a biotechnology company specializing in the use of stem cell technology to manufacture disease relevant cell based assay systems, announce they have formed a strategic partnership for the delivery of off-the-shelf and on-demand genomically modified and differentiated iPS cells.
Axol Bioscience, a biotechnology company, specialising in the use of stem cell technology to manufacture disease relevant cell based assay systems to the drug discovery industry, today announced the appointment of Sanj Kumar to the position of Chief Business Officer, an experienced and successful life science executive, well known for establishing and growing life science businesses, most recently at DiscoveRx ltd.
Chesterford Research Park is delighted to announce Axol’s arrival at the Park. Previously based at Babraham Research Campus, Axol’s move to Chesterford has been necessitated by the organic growth of its business, as a result of the expansion of its product lines and the resulting uptake of its products by customers, making an expansion of its R&D and production facilities necessary.